Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccine Booster with or without GM-CSF in Resected Melanoma
NCT00089063Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Jun 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in melanoma, sponsored by National Cancer Institute. Started Jun 2004; status: completed.
02
Drugs
sargramostim
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00089063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089063.